- Home
- BOWN vs SCYX Comparison
BOWN vs SCYX Comparison
Compare BOWN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOWN
- SCYX
- Stock Information
- Founded
- BOWN 2023
- SCYX 1999
- Country
- BOWN United States
- SCYX United States
- Employees
- BOWN N/A
- SCYX N/A
- Industry
- BOWN
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- BOWN
- SCYX Health Care
- Exchange
- BOWN Nasdaq
- SCYX Nasdaq
- Market Cap
- BOWN 28.5M
- SCYX 28.5M
- IPO Year
- BOWN 2023
- SCYX 2014
- Fundamental
- Price
- BOWN $9.20
- SCYX $0.76
- Analyst Decision
- BOWN
- SCYX
- Analyst Count
- BOWN 0
- SCYX 0
- Target Price
- BOWN N/A
- SCYX N/A
- AVG Volume (30 Days)
- BOWN 2.5K
- SCYX 178.0K
- Earning Date
- BOWN 01-01-0001
- SCYX 08-07-2025
- Dividend Yield
- BOWN N/A
- SCYX N/A
- EPS Growth
- BOWN N/A
- SCYX N/A
- EPS
- BOWN 0.02
- SCYX N/A
- Revenue
- BOWN N/A
- SCYX $2,630,000.00
- Revenue This Year
- BOWN N/A
- SCYX $463.61
- Revenue Next Year
- BOWN N/A
- SCYX $310.80
- P/E Ratio
- BOWN $201.47
- SCYX N/A
- Revenue Growth
- BOWN N/A
- SCYX N/A
- 52 Week Low
- BOWN $2.71
- SCYX $0.66
- 52 Week High
- BOWN $19.77
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- BOWN 43.24
- SCYX 57.99
- Support Level
- BOWN $9.14
- SCYX $0.67
- Resistance Level
- BOWN $10.20
- SCYX $0.83
- Average True Range (ATR)
- BOWN 0.39
- SCYX 0.04
- MACD
- BOWN -0.03
- SCYX 0.02
- Stochastic Oscillator
- BOWN 39.35
- SCYX 94.12
About BOWN Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.